Are you Dr. Chu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 48 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2301 Renaissance Blvd
Rn0320
King Of Prussia, PA 19406Phone+1 610-787-3490Fax+1 610-787-7043- Is this information wrong?
Summary
- Dr. Myron Chu, DO is a rheumatologist in King Of Prussia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, New Jersey, and Indiana.
Education & Training
- Loma Linda University Health Education ConsortiumFellowship, Rheumatology, 1995 - 1997
- University of Arizona College of Medicine-PhoenixResidency, Internal Medicine, 1992 - 1995
- Tucson Hospitals Medical EducationInternship, Transitional Year, 1991 - 1992
- College of Osteopathic Medicine of the PacificClass of 1991
Certifications & Licensure
- CA State License 1995 - 2026
- NJ State License 2000 - 2025
- AZ State License 1992 - 2025
- IN State License 1998 - 2025
- PA State License 2002 - 2024
Awards, Honors, & Recognition
- Fellow (FACP) American College of Physicians, 2006
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- 4 citationsPhase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.Fengchun Zhang, Jie Zheng, Yang Li, Guochun Wang, Mingjun Wang, Yin Su, Jieruo Gu, Xingfu Li, Myron Chu, Paula Curtis, Kathleen DeRose, Regina Kurrasch, Jenny Lowe, Pa...> ;RMD Open. 2022 Apr 1
- 14 citationsLong-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Ko...Yoshiya Tanaka, Sang Cheol Bae, Paula S. Curtis, Myron Chu, Kathleen DeRose, Beulah Ji, Regina Kurrasch, Jenny Lowe, Paige Meizlik, David M. Roth> ;RMD Open. 2021 Jul 1
- 165 citationsA pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South KoreaFengchun Zhang, Sang Cheol Bae, Damon Bass, Myron Chu, Sally Egginton, David Gordon, David M. Roth, Jie Zheng, Yoshiya Tanaka> ;Annals of the Rheumatic Diseases. 2018 Jan 2
- Join now to see all
Professional Memberships
- Member
- Fellow
- Fellow